Engineering Vascularized Skeletal Muscle Tissues with Adipose-derived Stem Cells
Engineering Vascularized Skeletal Muscle Tissues with Adipose-derived Stem Cells
批准号:
9468524
负责人:
Jordana Gilbert-Honick
金额:
$4.4万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-04-01 至 2020-03-31
关键词:
Adipose tissueAffectAllogenicAmputationAutologousBiochemicalBiocompatible MaterialsBlood VesselsBundlingCD34 geneCell SurvivalCell TransplantationCellsChronicCuesDefectDegenerative DisorderDevelopmentEngineeringEnvironmentFGF2 geneFiberFibrinFibrosisForskolinGoalsHumanImmune systemImplantIn VitroIndividualInjuryMechanicsMediatingMetabolicMorbidity - disease rateMusMuscleMuscular AtrophyMyoblastsNatural regenerationOperative Surgical ProceduresOutcomeOximesPECAM1 genePatient-Focused OutcomesPatientsPopulationPopulation HeterogeneityPropertySiteSkeletal MuscleSkeletal MyoblastsSourceStem cellsStructureSurgical FlapsTestingTissue DonorsTissue EngineeringTissuesTraumaVascular GraftWorkcell typeclinically relevantclinically translatablecombatimprovedin vivoin vivo Modelmuscle engineeringmuscle regenerationmuscle stiffnessmyogenesisnovelparacrinepromoterregenerativerepairedresponsestem cell differentiationsuccesstumor ablationvascular tissue engineering
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/ Abstract: The goal of this project is to create a tissue engineered vascularized skeletal
muscle construct. Volumetric muscle loss (VML) is a muscle defect that impacts greater than 20% of the
volume of an individual muscle, overwhelming the natural repair mechanisms and leading to chronic functional
deficits in the affected muscle. Current treatment options for VML are limited by donor site morbidity, lack of
donor tissue, and the need for a highly skilled surgical team. Developing a tissue engineered vascularized
skeletal muscle construct would mitigate these complications and provide a clinically-relevant treatment for
VML. An ideal cell source for skeletal muscle tissue engineering, adipose-derived stem cells (ASCs) have high
proliferation rates, can directly differentiate into myoblasts, and evade the host immune system. ASCs will be
grown on novel electrospun fibrin fibers that mimic the environment of native muscle by providing a muscle-like
stiffness and topographic alignment cues to encourage ASC myogenesis in 3D. The fibers provide a number of
advantages: they mimic the structure and mechanics of native muscle, are composed of a biological material
yet can be manufactured reproducibly, and they integrate well with host tissue causing minimal fibrosis.
The objective of the proposed study is to effectively overcome two major limitations associated with
ASC-mediated tissue engineered skeletal muscle and enable functional regeneration of a VML defect. First,
the efficiency of ASC differentiation into skeletal myoblasts will be increased. ASCs are a highly heterogeneous
population and narrowing ASCs to a potentially pro-myogenic CD34+CD31- subpopulation in a myomimetic 3D
microenvironment may result in significantly higher levels of myoblast differentiation, which will be necessary to
obtain a contractile muscle graft. Second, a strategy to rapidly vascularize the tissue engineered constructs to
maximize post-transplantation cell survival and integration of the engineered graft with the host tissues will be
developed. Native skeletal muscle is heavily vascularized and increasing vasculature within muscle defects
has been shown to improve muscle regeneration. Vascularized muscle constructs will be developed by
bundling ASC-derived skeletal muscle grafts with fibers containing engineered vascular networks comprised of
ASCs and endothelial progenitor cells (EPCs). The development of a vascularized muscle construct is likely to
further enhance the in vivo regenerative potential of ASCs and their clinical translatability. In Specific Aim 1
the myogenic capabilities of CD34+CD31- ASC subpopulation versus unsorted ASCs on electrospun fibrin
fibers will be compared. In Specific Aim 2 a 3D vascularized fibrin construct will be developed in vitro and its
incorporation into host vasculature will be investigated in vivo. In Specific Aim 3 a vascularized muscle
construct will be developed in vitro and its ability to enhance in vivo muscle regeneration in a VML defect will
be assessed. This work will enable the development of a vascularized skeletal muscle construct with easily
procurable cell types and off-the-shelf biomaterials that would provide a clinically-relevant treatment for VML.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金